EUROCINE VACCINES AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.042 SEK | -11.02% |
|
-47.50% | -8.70% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eurocine Vaccines AB is a Sweden-based clinical-stage company, which develops nasal vaccines. The Company develops vaccines up to proof of concept (clinical phase I/II) and license to partners for further development and commercialization. Also, the Company offers license partners vaccine adjuvant technologies, which are a key element of the nasal vaccines, for development in various indications. For these purposes the Companyâs uses its clinically validated technology Endocine. In addition, the Companyâs primary project is the nasal quadrivalent influenza vaccine Immunos FLU that aims for children from six month. The Company cooperates with both academic researchers and contract businesses and owns all income generated in these collaborations.
Calendar
2024-05-21
- Q3 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.70% | 835K | |
| +29.03% | 48.16B | |
| -0.10% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.48% | 25.59B | |
| -22.74% | 18.96B | |
| +9.06% | 12.92B | |
| +30.01% | 12.03B | |
| -1.51% | 11.77B |
- Stock Market
- Equities
- EUCI Stock
- News Eurocine Vaccines AB
- Eurocine Vaccines Receives Patent Coverage In South Korea For Vaccine Candidate
